53 related articles for article (PubMed ID: 10385131)
1. Systemic beta-blockade with once daily Betimol or Timoptic-XE.
Stewart WC; Cate EA; Stewart JA
J Ocul Pharmacol Ther; 1999 Jun; 15(3):225-31. PubMed ID: 10385131
[TBL] [Abstract][Full Text] [Related]
2. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
3. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily.
Shedden AH; Laurence J; Barrish A; Olah TV
Doc Ophthalmol; 2001 Jul; 103(1):73-9. PubMed ID: 11678162
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men.
Dickstein K; Aarsland T
Am J Ophthalmol; 1996 Apr; 121(4):367-71. PubMed ID: 8604729
[TBL] [Abstract][Full Text] [Related]
5. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.
Ishii Y; Nakamura K; Tsutsumi K; Kotegawa T; Nakano S; Nakatsuka K
J Clin Pharmacol; 2000 Feb; 40(2):193-9. PubMed ID: 10664926
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.
Stewart WC; Stewart JA; Crockett S; Kubilus C; Brown A; Shams N
Acta Ophthalmol Scand; 2002 Jun; 80(3):272-6. PubMed ID: 12059865
[TBL] [Abstract][Full Text] [Related]
7. Ocular tolerability of timolol in Gelrite in young glaucoma patients.
Nelson MD; Bartlett JD; Corliss D; Karkkainen T; Voce M
J Am Optom Assoc; 1996 Nov; 67(11):659-63. PubMed ID: 8979658
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy.
Stewart WC; Stewart JA; Jackson AL
Acta Ophthalmol Scand; 2002 Jun; 80(3):277-81. PubMed ID: 12059866
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure.
Stewart WC; Leland TM; Cate EA; Stewart JA
J Glaucoma; 1998 Dec; 7(6):402-7. PubMed ID: 9871862
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG).
Ohno Y; Iga T; Yamada Y; Nagahara M; Araie M; Takayanagi R
Curr Eye Res; 2005 Apr; 30(4):319-28. PubMed ID: 16020262
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel.
Bonnin N; Nezzar H; Dubray C; Renault D; Olmiere C; Chiambaretta F
J Fr Ophtalmol; 2012 Jan; 35(1):9-16. PubMed ID: 21992993
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
[TBL] [Abstract][Full Text] [Related]
13. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
[TBL] [Abstract][Full Text] [Related]
14. Differences in ocular surface irritation between timolol hemihydrate and timolol maleate.
Stewart WC; Stewart JA; Holmes KT; Leech JN
Am J Ophthalmol; 2000 Dec; 130(6):712-6. PubMed ID: 11124288
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma.
Halper LK; Johnson-Pratt L; Dobbins T; Hartenbaum D
J Ocul Pharmacol Ther; 2002 Apr; 18(2):105-13. PubMed ID: 12002664
[TBL] [Abstract][Full Text] [Related]
16. Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days.
McCrea JB; Vlasses PH; Franz TJ; Zeoli L
Pharmacotherapy; 1990; 10(4):289-93. PubMed ID: 2388875
[TBL] [Abstract][Full Text] [Related]
17. Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers.
Mundorf TK; Ogawa T; Inui N; Naka H; Novack GD; Crockett RS
Curr Med Res Opin; 2005 Mar; 21(3):369-74. PubMed ID: 15811205
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group.
Adamsons I; Clineschmidt C; Polis A; Taylor J; Shedden A; Laibovitz R
J Glaucoma; 1998 Aug; 7(4):253-60. PubMed ID: 9713783
[TBL] [Abstract][Full Text] [Related]
19. Interaction of naloxone and timolol on maximal exercise capacity and the subjective perception of fatigue.
Gullestad L; Dolva LO; Aase O; Kjekshus J
Int J Sports Med; 1989 Aug; 10(4):259-63. PubMed ID: 2606592
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of befunolol, betaxolol and timolol eye drops.
Dorigo MT; Cerin O; Fracasso G; Altafini R
Int J Clin Pharmacol Res; 1990; 10(3):163-6. PubMed ID: 1977708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
